Accelr8 Announces Results in Award-Winning Presentation for Rapid Diagnostics with ICU Specimens
September 19 2011 - 10:45AM
Business Wire
Accelr8 Technology Corporation (NYSE Amex: AXK) announced
results presented at the 51st ICAAC held in Chicago on September
17. As previously announced in July, the presenters received an
award for an “outstanding presentation of an abstract accepted by
ICAAC.” The presentation title is “Same-Shift ID Directly from
Respiratory Specimens by Automated Microscopy.” It reported results
from a study using Accelr8’s BACcel™ rapid diagnostic system in
collaboration with investigators at the Barnes-Jewish Hospital in
St. Louis.
The study reported results with 53 bacteria-positive lung
specimens from ICU patients. Of these, 16 were positive for the two
most common ICU pathogens that can express multi-drug resistance
(MDR)—Staphylococcus aureus (the common “Staph”) and Pseudomonas
aeruginosa. The latter Gram-negative organism is one of the most
complex and difficult to treat MDR threats found in
hospital-acquired infections.
Accelr8’s BACcel™ rapid diagnostic system correctly identified
9/9 S. aureus and 7/7 P. aeruginosa directly from specimen samples.
It also correctly identified the lack of these target organisms in
the remaining 37 specimens, yielding detection sensitivity and
specificity of 100% and 100%, respectively. The Accelr8 Web site
has a downloadable copy of the presentation at
www.accelr8.com/pgen.php?pg=resources_publications.
ICAAC (www.icaac.org) is the annual Interscience Conference on
Antimicrobial Agents and Chemotherapy. Organized by the American
Society for Microbiology (www.asm.org), ICAAC is a major global
congress for Clinical Microbiology and Infectious Diseases
Medicine.
According to David Howson, Accelr8’s president, “We are honored
by the recognition from ICAAC’s review committee. Results in our
outside studies continue to strongly support the system’s accuracy
and speed. The BACcel™ system continues as the only new technology
to demonstrate multiple organism quantitative identification with
multiple antibiotic resistance detection. The BACcel system stands
alone in directly confronting the relentlessly advancing global
pandemic of multiple antibiotic resistance.”
About Accelr8
Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative
materials and instrumentation for advanced applications in medical
instrumentation, basic research, drug discovery, and bio-detection.
Accelr8 is developing a rapid analytical platform for infectious
pathogens, the BACcel™ system, based on its innovative surface
coatings, assay processing, and detection technologies. In
addition, Accelr8 licenses certain of its proprietary technology
for use in applications outside of Accelr8’s own products.
Certain statements in this news release may be “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Statements regarding future prospects and
developments are based upon current expectations and involve
certain risks and uncertainties that could cause actual results and
developments to differ materially from the forward-looking
statement, including those detailed in the company's filings with
the Securities and Exchange Commission. Accelr8 does not undertake
an obligation to publicly update or revise any forward-looking
statements, whether as a result of new information or future
events.
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jul 2023 to Jul 2024